Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.90 7.50 8.30 7.90 7.90 7.90 392 07:46:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.0 -1.5 -0.5 - 30

Eden Research Share Discussion Threads

Showing 9476 to 9499 of 9850 messages
Chat Pages: Latest  382  381  380  379  378  377  376  375  374  373  372  371  Older
DateSubjectAuthorDiscuss
26/8/2020
06:58
Hillofwad - agreed. Unbelievable: they find oil, as it were, under the new office chairs, and still manage to stuff it up.
erinvale
26/8/2020
05:44
However they go forward carrying a heavy legacy burden which is unlikely to play out well for the private investor . The only ones who managed to trouser anything here is those who got out at 20p sometime ago Without the milestone paymnents they would have gone west.Their distributors became lenders of last resort and as such were able to negotiate deals highly skewed to themselves The prospect of any sort of dividends to the private investor here at the bottom of the heap looks way down the line Gratifictaion deferred ? What is likely to happen here is that Eden will run short of cash when one of their expensive research projects bombs having accumulated no ballast to cover the evntuality and somebody will pick this up cheaply
hillofwad
25/8/2020
16:46
Could be fat finger problem..I've inadvertently ticked up a post before now.but as a non person pleb on here I can't red tick anyone...god how I wish I could sometimes...might be worth signing up just for the pleasure....
33mick
25/8/2020
15:49
Investing... I'm trying to work out why anyone would give you a down tick on your sensible, factual and pertinent post ?
speculator59
25/8/2020
13:21
You're all talking about the past, but in my opinion should focus on the here and now and what lies in front. The business model has changed, the board has changed, the distributors, partners and investors have changed. If you don't like the Eden story, jog off elsewhere. If you do like the Eden story, no doubt you're frustrated, as I am, but if you're staying invested, as I am, you're likely anticipating positive change. Let's see where we end up. That's all there is to it.
investingisatrickygame
25/8/2020
11:50
33mick it is interesting to trace through the original approval for the Southern Group of EU via Malta and then look how long it took individual countries to give approval. France and ?Portugal took nearly 2 years when officially allowed 120 days ? They are major markets. But there is change afoot when we look at Cedroz with Italy etc. gaining emergency approvals because there are no other effective solutions. Eden is always going to be a jam tomorrow share - until that indefinable moment that it happens. It will, but my concern has always been that it will be taken over on the cheap.
speculator59
25/8/2020
09:21
Sorry I should say sales in sufficient quantity to stem the horrendous consumption of investor capital. I didnt rustle up that £35m figure, believe it or not it is the amount people like you and I have fronted up that has been spent to achieve not enough.
quazie12
25/8/2020
09:18
InvestingYou say that "Regulatory approvals will lead to sales."Can you cite good reason why the literally hundreds of regulatory approvals over the years have not really amounted to sales to date (5 years for SS and over 25 years for the company) ? I can't.
quazie12
25/8/2020
09:14
"Eden should replace Sipcam if the product is really effective" Can they? Herein lies the rub.Tail wagging the dog .You can bet your last dollar that it will be Sipcam calling all the shots here and controlling the contract . It does look that the amount Eden extract from each sale is a pittance
hillofwad
25/8/2020
08:55
From Eden's 2015 annual report: “Now that the Company has received funding to accelerate its growth and development, as well as key EU approvals for 3AEY, Eden is well placed to exploit its patents, know-how, technologies and products and drive commercialisation on apace'. Sales 2019 - £2.04m - operating loss £1.357m. Progress?
erinvale
25/8/2020
08:29
@erinvale Eden in its previous guises, with previous management, so beit. But let's judge Sean Smith and the last 5 years. Quite a lot has been achieved during that period for a company that is in the market and environment that Eden is. Granted, we now all want to see sales and that requirement is justified. We sit with Mevalone and a widening global reach, a product that is affected by seasonality, but hopefully, global reach and differing climates will smooth this out. Sipcam has the opportunity to provide the Australian market with ample product in readiness for their summer/Autumn period. The onus of sales is on Sipcam, not Eden and Eden should replace Sipcam if the product is really effective, yet Sipcam fails to sell it. That to me is the only argument regarding sales that can be levied at Eden. Cedroz is in the regulatory phase. This year has been unprecedented so some disruption is understandable, but working from home and connections to corporate servers should be standard. So yes, we all hope and expect regulatory approvals for Cedroz to speed through now. Maybe Mike Carroll has some assistive role to play with Eastman to aid progress. Corteva and Seeds - We await the outcome at the end of this year as RNS'd which in isolation could establish annual net sales to Eden, as RNS'd, equal to the value that quizie12 wants to push in their post 8035 (£36 million. Eden's communications still doesn't hit the investor community trigger of "I must/should invest" and it will take a bold step by Eden to correct that. Regulatory approvals are pending with no reason to expect rejections. Regulatory approvals will lead to sales. None of the above takes into account unknown/pending/future commercial agreements to deliver future value to Eden and its shareholders. None of this takes into account Eden's commercial "jack in the box" which is Sustaine. Aside of new agreements, Eden and Sipcam has still yet to RNS the outcome of their commercial collaboration on the same and I think a holding statement is long overdue and one which Eden should acknowledge and therefore comment on.
investingisatrickygame
25/8/2020
07:59
They needed the milestone payments from their partners just to keep the lab.lights on Like a football club selling its future season ticket sales The long and short of it with pedestrian sales Eden are left with half of SFA going forward Even opening up new territories the only real beneficaries are the distributors Certainly hasn't justified the investment
hillofwad
25/8/2020
07:46
Yes, investing... but they've been at it for quarter of a century and still have not managed to achieve decent sales. If they were in wheelchairs, instead of office chairs, we'd probably all be buying.
erinvale
25/8/2020
07:43
Eden is in the business of R & D, product trials, partnering, regulatory approvals, distribution agreements and then sales. There is no point moaning about today's approval. It is terrific news. Wait till the year-end report or/and a Company update between now and then to judge sales of Mevalone in Australia in its inaugural season in this country.
investingisatrickygame
25/8/2020
07:40
Aha!,so that's the reason for the tick up yesterday afternoon.
2 risky
25/8/2020
07:28
Quazie12 - thanks. A very interesting statistic. Each approval = 10 good office chairs. Phew!
erinvale
25/8/2020
07:26
Babble on Babbler.Cedroz (sorry I forgot Malta in there) is a product used to treat a pest prevalent in vegetables and fruits. I think you will find that today's approval (one of literally hundreds that have been rns'd over the years) is a botrytis treatment more specifically for grapes. My whole point is this, lets say conservatively there have been over 200 rns approvals by Eden then that represents £2k revenue per approval rns ffs
quazie12
25/8/2020
07:21
bjik - absolutely. This is another office chair. Eden will not prosper until it sells product in large, sustainable, quantities. As yet, there is no evidence of that happening. Let's hope it will before the office is choc-a-bloc with new chairs.
erinvale
25/8/2020
07:12
What is Unmentionable refering to?? "The approval also represents a geographical expansion for our business, and we look forward to continuing our work with Sipcam to increase our activities in the region." ASIA – PACIFIC ??? hTTp://www.sipcam-oxon.com/public/companies/#america-s hTTps://www.investegate.co.uk/eden-research-plc--eden-/rns/new-authorisation-for-bio-fungicide-in-australia/202008250700040117X/
supersonico
25/8/2020
07:07
wan, With all due respect, why post 1082 today? Australia has just been approved hence todays RNS. You will need to wait for the year-end report to understand Eden's sales success of Novellus to Australia. To my mind, there is no point criticising on the day of a positive RNS. The door to Australia is now open and clearly Sipcam has to penetrate that market. What you could reasonably comment on would be to enquire if Eden/Sipcam might further comment on how and when they expect to enter the Australian market with sales success. I don't expect Eden to do that as they haven't before, but given the Australian opportunity, it would be welcome commentary to give investors a country roadmap.
investingisatrickygame
25/8/2020
06:47
Investors should investigate themselves that Mevalone is joining the long list of other 'already' authorised Australian grape biofungicides, including from the large global players. The wine industry in Australia has not been left untouched by the current wine/vineyard crisis, and authorisation alone does not mean success. That will come from demonstrating actual and meaningful sales and not potential, meaningful sales and sales growth is where Eden has routinely and constantly failed to live up to expectation.
wan
25/8/2020
06:22
Awwwh that's brilliant, there was one more spot in Shauns downstairs bathroom to fit another approval... if there are anymore approvals he has no more room on his walls so he might finally be incentivised to actually sell something to pay for an extension ... I knew Sean would eventually have to sell something...
bjlk
25/8/2020
06:19
Australia any better for you?
babbler
25/8/2020
06:12
New authorisation for bio-fungicide in Australia hTTps://www.investegate.co.uk/eden-research-plc--eden-/rns/new-authorisation-for-bio-fungicide-in-australia/202008250700040117X/
supersonico
Chat Pages: Latest  382  381  380  379  378  377  376  375  374  373  372  371  Older
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201130 04:56:04